Growth in health spending ‘grinds to a halt’
June 28, 2012Business Services, Sales and Marketing Financial, GDP, OECD, growth, pharma
Growth in health spending slowed or fell in real terms in 2010 in almost all OECD countries, reversing a long-term …
DH admits cancer awareness campaigns failed
June 28, 2012Sales and Marketing Cancer, Department of Health, GPs, government
The government’s £9 million cancer awareness campaigns were built upon failed pilots, according to newly released data. The national awareness …
US judges vote to keep Obamacare
June 28, 2012Sales and Marketing Health reform, President Obama, US
The US Supreme Court will allow President Obama’s health reforms to stand.The nine-member Supreme Court has decided not to repeal …
Microsoft buys Yammer for $1.2 billion
June 28, 2012Medical Communications Daiichi Sankyo, Facebook, Microsoft, Yammer, social network
Microsoft has acquired Yammer, an internal social networking system for businesses, for $1.2 billion. Set up in 2008, Yammer closely …
MRN gets SMART with its clinical trial scheduling
June 28, 2012Research and Development clinical trials, electronic data capture, medical research network, mrn, patient scheduling
Medical Research Network (MRN), the unique Clinical Trial Support Organisation (CTSO) offering home trial and site nurse support as well …
ZS Associates elects new managing director
June 28, 2012Business Services, Medical Communications, Sales and Marketing Chris Wright, ZS Associates
Sales and marketing consulting firm ZS Associates announced today that Chris Wright has been elected by firm partners to the …
Ireland agrees deal on medicines
June 28, 2012Business Services, Sales and Marketing AstraZeneca, IPHA, Ireland, Lundbeck, Novartis, pricing
Ireland’s pharmaceutical industry has agreed a deal with the country’s government which breaks a deadlock over prices and access. The …
Apps not the way forward for trial recruitment
June 28, 2012Medical Communications Pfizer, apps, digital, virtual trial
After Pfizer admitted defeat in the first ever ‘virtual trial’ earlier this year, it seems that we are not yet …
FDA clears Arena and Eisai’s obesity drug
June 28, 2012Sales and Marketing Arena, Belviq, Eisai, FDA, Qnexa, Roche, obesity
Eisai and Arena’s Belviq has gained FDA approval, making it the first obesity drug to be approved in over ten …
Astellas submits new prostate cancer drug to EMA
June 28, 2012Research and Development, Sales and Marketing Astellas, EMA, Medivation, NICE, Zytiga, enzalutamide
Astellas has submitted its investigational prostate cancer drug enzalutamide to the European Medicines Agency. Enzalutamide is a once-daily pill that works …
Witty warns EU leaders over pricing
June 27, 2012Sales and Marketing EFPIA, EU, GSK, Greece, R&D, Witty, pricing
Sir Andrew Witty has waded into the debate over Europe’s economic future with a plea for pharma innovation to be …
ABPI to no longer ‘shy away’ from big issues
June 27, 2012Medical Communications, Sales and Marketing ABPI, Callaghan, NHS, VBP, Whitehead
The ABPI will actively seek to tackle tough issues like animal testing and clinical trial problems, as it looks to …
NICE final yes for Zytiga and Tarceva
June 27, 2012Sales and Marketing Janssen, NHS, NICE, NSCLC, Roche, Tarceva, Zytiga
In final guidance published today, NICE is recommending two new drugs for patients with prostate and lung cancer. Janssen’s Zytiga …
Amylin withheld safety data, says FDA
June 27, 2012Research and Development, Sales and Marketing Amylin, Bydureon, Byetta, FDA, lilly
The US medicines regulator says Amylin held back data relating to the safety of its diabetes drug Bydureon. The allegation …
CSL Behring launches new dosing app
June 27, 2012Medical Communications Beriplex P/N, CSL Behring, app, digital
Biotherapy firm CSL Behring UK has launched an app for doctors to aid the management of its anaesthetic treatment Beriplex …
Eisai to enter Russia with epilepsy launch
June 27, 2012Sales and Marketing Eisai, Russia, Zonegran, emerging markets, epilepsy
Eisai is to enter the Russian market for the first time with the launch of epilepsy drug Zonegran. Entry into the …
Roche cuts 1,000 R&D jobs
June 27, 2012Research and Development, Sales and Marketing AZ, Genentech, Novartis, R&D, Roche, cuts
Roche will make major cuts to its research operations in the US and revamp operations in Europe. Roche will close …
Roche’s Perjeta increases survival
June 27, 2012Research and Development, Sales and Marketing EMA, FDA, Herceptin, Perjeta, Roche, breast cancer
Roche’s new drug Perjeta has scored another trial success by increasing overall survival in certain breast cancer patients. The new …
London Trust on the brink of going bust
June 26, 2012Sales and Marketing Lansley, NHS, South London Healthcare, reforms
For the first time in its history an NHS Trust is facing bankruptcy and could be dissolved by the government. …
Generic approval for Shire’s hyperactivity drug
June 26, 2012Sales and Marketing ADHD, Adderall XR, FDA, IMS Health, Impax, Shire, Teva
US regulators have delivered a blow to Shire by allowing Actavis Group to produce a generic version of its hyperactivity …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
